Linzagolix

• Target:

  GNRH Receptor

• Related Pathways:

  GPCR/G Protein

• Purity:

  0.9968

• Bioactivity:

  Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.

• Smiles:

  COc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O

• Molecular Formula:

  C22H15F3N2O7S

• Molecular Weight:

  508.42

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  935283-04-8